Biocon is currently trading at Rs. 417.70, up by 9.10 points or 2.23% from its previous closing of Rs. 408.60 on the BSE.
The scrip opened at Rs. 410.00 and has touched a high and low of Rs. 418.60 and Rs. 405.80 respectively. So far 189404 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 427.95 on 21-Nov-2017 and a 52 week low of Rs. 280.39 on 23-Nov-2016.
Last one week high and low of the scrip stood at Rs. 427.95 and Rs. 379.15 respectively. The current market cap of the company is Rs. 25089.00 crore.
The promoters holding in the company stood at 60.67%, while institutions and non-institutions held 19.23% and 20.10% respectively.
Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.
KRABEVA, a monoclonal antibody (mAb) developed by Biocon, will help expand access to a world class, high quality biosimilar Bevacizumab for cancer patients in India. It is the world's first and only Bevacizumab with a unique 'Qual-Check' mechanism, which will ensure that patients get a quality-ascertained product right upto infusion.
Bevacizumab is indicated as a first-line treatment of patients with metastatic colorectal cancer (mCRC), and is accepted as a standard treatment option in combination with chemotherapy for patients with non-small-cell lung cancer (NSLC), metastatic renal cell carcinoma and recurrent ovarian cancer.
Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.